Source:http://linkedlifedata.com/resource/pubmed/id/17116133
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2006-11-22
|
| pubmed:abstractText |
We have retrospectively analyzed the incidence of cytomegalovirus (CMV) infection in 250 consecutive renal allograft transplants performed in 244 recipients. The mean follow-up was 35.1+/-25.4 months. Immunosuppression was cyclosporine- or tacrolimus-based triple therapy. CMV infection prophylaxis with ganciclovir for 3 months post transplant was prescribed in CMV-seronegative recipients of allografts from seropositive donors (D+R-) and in all recipients treated with OKT3. CMV antigenemia was monitored by the pp65-antigen assay. Thirteen of 57 D+R- recipients (22.8%) developed CMV antigenemia. One recipient had a breakthrough of CMV antigenemia during ganciclovir prophylaxis; 12 D+R- recipients developed CMV antigenemia 147.5+/-173.8 days after transplantation. Four of 13 (30.7%) D+R- recipients had asymptomatic CMV infection, 8 (61.6%) had CMV infection with non-specific symptoms including fever, and 1 (7.7%) developed CMV pneumonia. Six of 13 (46.1%) D+R- patients had been treated with intensified immunosuppressive therapy before CMV infection. In the low-risk CMV groups (D+R+; D-R+; D-R-), 28 recipients (14.5%) developed CMV antigenemia 42.5+/-15.2 days post transplantation. Ten of the 28 (35.7%) recipients had asymptomatic CMV infection, 17 (60.7%) developed CMV infection with non-specific symptoms, and 1 (3.6%) developed CMV pneumonia. Twenty-one of 28 (75.0%) had intensified immunosuppressive therapy before CMV infection. In conclusion, ganciclovir prophylaxis diminished and delayed the onset of CMV infection but did not totally prevent it from occurring in D+R- renal transplant recipients. Clinicians should be vigilant to the possibility of CMV infection in both seronegative and seropositive recipients, especially after anti-rejection therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1398-2273
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
203-12
|
| pubmed:meshHeading |
pubmed-meshheading:17116133-Adult,
pubmed-meshheading:17116133-Cytomegalovirus Infections,
pubmed-meshheading:17116133-Female,
pubmed-meshheading:17116133-Ganciclovir,
pubmed-meshheading:17116133-HLA-DR Antigens,
pubmed-meshheading:17116133-Humans,
pubmed-meshheading:17116133-Immunosuppressive Agents,
pubmed-meshheading:17116133-Kidney Transplantation,
pubmed-meshheading:17116133-Male,
pubmed-meshheading:17116133-Middle Aged,
pubmed-meshheading:17116133-Retrospective Studies
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Cytomegalovirus infection in renal transplant recipients.
|
| pubmed:affiliation |
Department of Renal Medicine, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark. jcar@farm.au.dk
|
| pubmed:publicationType |
Journal Article
|